BioCryst Pharmaceuticals (NASDAQ:BCRX) Price Target Raised to $14.00

BioCryst Pharmaceuticals (NASDAQ:BCRX) had its price objective lifted by analysts at Royal Bank Of Canada from $13.00 to $14.00 in a research report issued to clients and investors on Tuesday,Benzinga reports. The brokerage currently has an “outperform” rating on the biotechnology company’s stock. Royal Bank Of Canada’s target price suggests a potential upside of 37.86% from the company’s previous close.

Several other brokerages also recently commented on BCRX. Wedbush decreased their target price on shares of BioCryst Pharmaceuticals from $22.00 to $21.00 and set an “outperform” rating on the stock in a research note on Thursday, May 7th. Cantor Fitzgerald raised their price target on shares of BioCryst Pharmaceuticals from $27.00 to $29.00 and gave the stock an “overweight” rating in a report on Tuesday, June 30th. Wall Street Zen cut shares of BioCryst Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research report on Saturday, May 9th. HC Wainwright reaffirmed a “buy” rating and set a $32.00 price objective on shares of BioCryst Pharmaceuticals in a research note on Tuesday, June 30th. Finally, Needham & Company LLC lowered their price objective on shares of BioCryst Pharmaceuticals from $18.00 to $16.00 and set a “buy” rating for the company in a research note on Wednesday, May 6th. Eight equities research analysts have rated the stock with a Buy rating and three have issued a Hold rating to the company. According to MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $21.78.

BioCryst Pharmaceuticals Stock Down 0.1%

Shares of NASDAQ BCRX traded down $0.01 during mid-day trading on Tuesday, reaching $10.15. 1,522,312 shares of the company were exchanged, compared to its average volume of 5,192,985. BioCryst Pharmaceuticals has a 52 week low of $6.00 and a 52 week high of $10.94. The company’s 50 day moving average price is $8.99 and its 200 day moving average price is $8.35. The stock has a market capitalization of $2.58 billion, a PE ratio of -5.72 and a beta of 0.55.

BioCryst Pharmaceuticals (NASDAQ:BCRX) last released its earnings results on Wednesday, May 6th. The biotechnology company reported ($2.98) EPS for the quarter, missing analysts’ consensus estimates of $0.06 by ($3.04). The firm had revenue of $156.41 million during the quarter, compared to the consensus estimate of $151.12 million. BioCryst Pharmaceuticals had a negative net margin of 51.71% and a negative return on equity of 76.36%. The firm’s revenue was up 7.5% compared to the same quarter last year. During the same period in the prior year, the company earned $0.20 EPS. On average, sell-side analysts predict that BioCryst Pharmaceuticals will post -2.63 earnings per share for the current year.

Hedge Funds Weigh In On BioCryst Pharmaceuticals

A number of institutional investors have recently bought and sold shares of BCRX. Royal Bank of Canada grew its position in BioCryst Pharmaceuticals by 2.4% during the first quarter. Royal Bank of Canada now owns 63,463 shares of the biotechnology company’s stock valued at $476,000 after buying an additional 1,458 shares during the period. Cetera Investment Advisers increased its holdings in BioCryst Pharmaceuticals by 13.8% during the fourth quarter. Cetera Investment Advisers now owns 12,330 shares of the biotechnology company’s stock valued at $96,000 after buying an additional 1,494 shares during the last quarter. Captrust Financial Advisors raised its position in BioCryst Pharmaceuticals by 7.4% in the second quarter. Captrust Financial Advisors now owns 22,105 shares of the biotechnology company’s stock worth $198,000 after acquiring an additional 1,527 shares during the period. Counterweight Ventures LLC raised its position in BioCryst Pharmaceuticals by 2.1% in the fourth quarter. Counterweight Ventures LLC now owns 95,384 shares of the biotechnology company’s stock worth $744,000 after acquiring an additional 2,000 shares during the period. Finally, Mirae Asset Global Investments Co. Ltd. boosted its stake in shares of BioCryst Pharmaceuticals by 26.1% during the 4th quarter. Mirae Asset Global Investments Co. Ltd. now owns 10,231 shares of the biotechnology company’s stock worth $80,000 after acquiring an additional 2,115 shares during the last quarter. 85.88% of the stock is owned by institutional investors.

BioCryst Pharmaceuticals Company Profile

BioCryst Pharmaceuticals, Inc is a clinical‐stage biotechnology company headquartered in Durham, North Carolina, that focuses on the discovery and development of novel, oral small‐molecule medicines for rare and serious diseases. Since its founding in 1986, the company has leveraged structure‐based drug design to advance a pipeline of targeted therapeutics designed to address underlying disease mechanisms rather than just treat symptoms.

The company’s first commercial product, Orladeyo (berotralstat), is an oral kallikrein inhibitor approved for the prophylactic treatment of hereditary angioedema (HAE) in both the United States and Europe.